Celiac Disease Clinical Trial
— GFDLOfficial title:
Persistent Increase in the Intestinal γδ+ T-cell Subset: A Potential Biomarker of Coeliac Disease in Patients Started on a Gluten-free Diet
NCT number | NCT05733663 |
Other study ID # | GFDL |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2013 |
Est. completion date | December 31, 2020 |
Verified date | April 2023 |
Source | Hospital Mutua de Terrassa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Coeliac disease (CD) is a systemic process of autoimmune nature related to the existence of a permanent intolerance to gluten and manifests itself in genetically susceptible individuals. It has a global prevalence of 0.5-1.5%. The diagnosis of CD should be made in patients following a normal gluten-containing diet and is based on coeliac serology and histopathological changes of the small intestinal mucosa. However, nowadays many patients come to their doctor to rule out CD after having started a gluten-free diet (GFD) with improvement of symptoms. In this scenario, making the diagnosis of CD remains a challenge, as it must be considered that most CD-associated changes revert after gluten withdrawal. An essential finding of CD is the increased number in total intraepithelial lymphocytes (IEL) in the duodenal mucosa, later characterized by an expansion of γδ+ and CD8+ IEL coupled to a decrease in CD3- IEL. An accurate quantification of the γδ+ subset became possible with the introduction of flow cytometry. In 2002, Spanish investigators proposed a diagnostic algorithm for paediatric CD that included the combined use of a high percentage of γδ+ and a low percentage of CD3- IEL, which was termed the coeliac lymphogram, which has been shown to be very accurate for the diagnosis of CD. Thus, the use of flow cytometric phenotyping of IEL may strengthen the diagnosis of CD when it is not straightforward. This study will provide information about the potential usefulness of T-cell flow cytometric coeliac patterns as CD biomarkers to confirm the diagnosis of CD in patients who have already started a GFD. These results may help to make decisions in specific situations of routine clinical practice, avoiding bothersome gluten reintroduction and delays in diagnosis.
Status | Completed |
Enrollment | 116 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion criteria: - Paediatric or adult patients diagnosed with CD and started on a strict GFD - Patients with a follow-up intestinal biopsy to assess histological remission at least 1-year after starting the GFD - Assessment of the intraepithelial lymphogram at both baseline and follow-up - Presence of increased TCR?d+ cells at baseline. Exclusion criteria: - Refusal of the patient to participate in the registry. - Pregnancy and severe comorbidities (heart disease, chronic obstructive pulmonary disease, liver disease, bleeding disorders, etc). - Patients with intake of NSAIDs or Olmesartan. - Patients with Crohn's disease, autoimmune disease associated enteropathy, collagenous sprue, microscopic colitis, lymphocytic enteritis due to intestinal parasitosis or Helicobacter pylori infection, other enteropathies. - Selective IgA deficiency. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari Mutua Terrassa | Terrassa | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Hospital Mutua de Terrassa |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Frequency of persisting CD changes despite a GFD (i.e., positive CD serology, persistent villous atrophy) at the time of follow-up biopsy and compare them with the frequency of a persistent increase in ?d+ subset. | 1 year | ||
Primary | Percentage of long-term persistence of both the coeliac lymphogram (increase in TCR?d+ and decrease in CD3- cells) and the isolated increase in TCR?d+ cells measured by T-cell flow cytometry in CD patients after starting a GFD. | Lymphocyte subpopulations (TCR?d+ and CD3- cells) are measured by flow cytometry. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to baseline histology (measured by Marsh Classification: 0, 1, 2 or 3) | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to age group (measured by years). | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to gender (classified according to male or female sex). | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to coeliac serology (measured by presence or absence of anti-transglutaminase antibodies). | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to DQ-genotype (measured by presence or absence of HLA-DQ2.5). | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year | |
Secondary | Percentage of loss of the T-cell flow cytometric coeliac pattern (increase in TCR?d+) according to follow-up time (measured by years). | To assess the frequency of nonpersistence of the increased TCR?d+ subset related to study variables, the chi-square test, Fisher exact test, and the Freeman-Halton extension of the Fisher exact probability test for a 2x3 or a 2x4 contingency table were used. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04349904 -
Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
|
||
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Completed |
NCT04593251 -
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
|
Phase 1 | |
Completed |
NCT05810441 -
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
|
||
Recruiting |
NCT05555446 -
Bovine Colostrum to Prevent Absorption of Gluten
|
Early Phase 1 | |
Completed |
NCT02754609 -
Hookworm Therapy for Coeliac Disease
|
Phase 1 | |
Terminated |
NCT01902368 -
Celiac Disease Screening
|
N/A | |
Completed |
NCT02472704 -
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
|
N/A | |
Completed |
NCT02312349 -
Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
|
||
Completed |
NCT01172665 -
Celiac Disease Database
|
||
Completed |
NCT01100099 -
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00639444 -
Risk of Celiac Disease and Age at Gluten Introduction
|
N/A | |
Active, not recruiting |
NCT05425446 -
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
|
Phase 1 | |
Enrolling by invitation |
NCT02202681 -
Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule
|
N/A | |
Completed |
NCT00362856 -
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
|
Phase 2 | |
Terminated |
NCT03866538 -
Budesonide in Patients With Immune Mediated Enteropathies
|
Phase 4 | |
Recruiting |
NCT05135923 -
Glutenfree, Gut Microbiota and Metabolic Regulation
|
N/A | |
Completed |
NCT05052164 -
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
|
N/A | |
Completed |
NCT03775499 -
Probiotic BL NCC 2705 and Gluten Sensitivity
|
N/A | |
Completed |
NCT03707730 -
A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease
|
Phase 2 |